Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Aberrant mitochondrial fission is a pathogenic hallmark of myeloma and inhibition of mitochondrial fission GTPase DRP1 with Drpitor1a may be a promising therapeutic approach, especially for relapsed or refractory disease.”
Title: DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma
Authors: Maria Eugenia Gallo Cantafio, Noemi Puccio, Roberta Torcasio, Ilenia Valentino, Ludovica Ganino, Yuanyuan Jin, Anil Aktas Samur, Pierpaolo Murfone, Alessia Gallo, Mehmet K. Samur, Nicola Cuscino, Cesarina Giallongo, Ida Daniela Perrotta, Alessia Ciarrocchi, Federico Tallarigo, Ernestina Marianna De Francesco, Davide Barbuto, Ross David Jansen-van Vuuren, Luka Jedlovčnik, Danchen Wu, Enrica Antonia Martino, Daniele Tibullo, Francesco Di Raimondo, Massimo Gentile, Antonino Neri, Stephen L. Archer, Eugenio Morelli, Nikhil C. Munshi, Giuseppe Viglietto, Mariateresa Fulciniti, Nicola Amodio
You can read the full article on Blood.
You can find other articles featuring Robert Orlowski on OncoDaily.
